ES2572373T3 - Emulsiones aniónicas aceite en agua que contienen prostaglandinas y usos de las mismas - Google Patents

Emulsiones aniónicas aceite en agua que contienen prostaglandinas y usos de las mismas

Info

Publication number
ES2572373T3
ES2572373T3 ES10708178T ES10708178T ES2572373T3 ES 2572373 T3 ES2572373 T3 ES 2572373T3 ES 10708178 T ES10708178 T ES 10708178T ES 10708178 T ES10708178 T ES 10708178T ES 2572373 T3 ES2572373 T3 ES 2572373T3
Authority
ES
Spain
Prior art keywords
emulsion
oil
water emulsions
emulsions containing
surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10708178T
Other languages
English (en)
Inventor
Frédéric Lallemand
Betty Phillips
Jean-Sébastien Garrigue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen SAS
Original Assignee
Santen SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen SAS filed Critical Santen SAS
Application granted granted Critical
Publication of ES2572373T3 publication Critical patent/ES2572373T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Cosmetics (AREA)

Abstract

Una emulsión coloidal aceite en agua que comprende: - una prostaglandina F2alfa, - un aceite que tiene un valor de yodo <= 2, - un surfactante no iónico, y - agua, en donde el surfactante no iónico libera cargas negativas durante el proceso de fabricación de la emulsión, dicha emulsión tiene un potencial zeta negativo menor de -10 mV, el surfactante no iónico se selecciona entre poloxámeros, tiloxapol, polisorbatos, ésteres de sorbitán, estearatos de polioxilo o mezclas de los mismos, la cantidad del surfactante con relación al peso total de la emulsión está comprendida entre 0.0005 y 1 % p/p; y dicha emulsión no contiene alcohol polivinílico.
ES10708178T 2009-03-04 2010-03-04 Emulsiones aniónicas aceite en agua que contienen prostaglandinas y usos de las mismas Active ES2572373T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15734709P 2009-03-04 2009-03-04
EP09305203A EP2228058A1 (en) 2009-03-04 2009-03-04 Anionic oil-in-water emulsion containing prostaglandins and uses thereof
PCT/EP2010/052740 WO2010100217A1 (en) 2009-03-04 2010-03-04 Anionic oil-in-water emulsions containing prostaglandins and uses thereof

Publications (1)

Publication Number Publication Date
ES2572373T3 true ES2572373T3 (es) 2016-05-31

Family

ID=40626733

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10708178T Active ES2572373T3 (es) 2009-03-04 2010-03-04 Emulsiones aniónicas aceite en agua que contienen prostaglandinas y usos de las mismas

Country Status (12)

Country Link
US (1) US9089480B2 (es)
EP (2) EP2228058A1 (es)
JP (1) JP5722802B2 (es)
KR (2) KR101879381B1 (es)
CN (1) CN102341093B (es)
AU (1) AU2010220321B2 (es)
CA (1) CA2754156C (es)
ES (1) ES2572373T3 (es)
HK (1) HK1166608A1 (es)
IL (1) IL214506A (es)
MX (1) MX2011009256A (es)
WO (1) WO2010100217A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE412400T1 (de) * 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
CA2681668C (en) 2006-03-23 2014-04-01 Michael S. Singer Compositions comprising prostaglandin f2-alpha analogs and methods for reducing body fat
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
WO2012038469A2 (en) * 2010-09-21 2012-03-29 S&V Technologies Ag Cosmetic composition
EP3378480A1 (en) 2011-01-19 2018-09-26 Topokine Therapeutics, Inc. Methods and compositions for treating obesity
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
US20140322428A1 (en) * 2013-03-15 2014-10-30 Leading Edge Innovations, LLC Compositions having an oil-in-water dispersion of submicron particles to enhance foods and beverages
NO2753788T3 (es) * 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
PL427837A1 (pl) * 2018-11-22 2020-06-01 Gbj Pharma Spółka Z Ograniczoną Odpowiedzialnością Systemy do ciągłego obwodowego podawania latanoprostu dla obniżania ciśnienia śródgałkowego
CN111840225B (zh) * 2020-08-12 2021-09-14 陈丽娜 一种用于治疗青光眼的滴眼剂及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
JPH0818989B2 (ja) 1984-01-12 1996-02-28 株式会社ミドリ十字 脂肪乳剤中のプロスタグランジンの安定化方法
JP2602964B2 (ja) 1989-10-16 1997-04-23 裕 水島 プロスタグランジン類縁体およびその脂肪乳剤
IL101241A (en) 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
EP0631770B1 (en) 1993-06-25 1998-07-22 Alcon Cusi, S.A. New use of polymeric membranes in the dispensing of pharmaceutical solutions that contain quaternary ammonium compounds as preservatives and corresponding dose dispensor
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
FR2823441B1 (fr) 2001-04-12 2004-09-10 Thea Lab Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie et son procede de preparation
WO2002085248A2 (en) 2001-04-23 2002-10-31 Board Of Regents The University Of Texas System Prostanoids augment ocular drug penetration
JP2005513097A (ja) 2001-11-01 2005-05-12 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム ドライアイ治療方法および組成物
KR100446960B1 (ko) 2001-12-04 2004-09-01 김종국 프로스타글란딘 ｅ1을 포함하는 온도감응성 에멀젼 외용제조성물
US20050124699A1 (en) 2002-07-02 2005-06-09 Wakamoto Pharmaceutical Co., Ltd. Drugs for treating or preventing disorders of corneal and/or conjunctival epithelial cells
KR20100132557A (ko) 2002-08-23 2010-12-17 산텐 세이야꾸 가부시키가이샤 라타노프로스트를 유효 성분으로 하는 점안액의 안정화 방법
KR20050057251A (ko) 2002-09-09 2005-06-16 산텐 세이야꾸 가부시키가이샤 라타노프로스트를 유효 성분으로 하는 투명한 점안액
US20040115234A1 (en) 2002-09-24 2004-06-17 Gewirtz Joan T. Cosmetic composition
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
JP4762718B2 (ja) 2003-11-07 2011-08-31 千寿製薬株式会社 プロスタグランジン含有医薬組成物
ATE412400T1 (de) 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
EP1809238B1 (en) 2004-11-09 2008-10-29 Novagali Pharma SA Ophthalmic emulsions containing an immunosuppressive agent
CN101282714B (zh) 2005-10-10 2012-12-12 诺瓦加利制药公司 包含前列腺素的眼用乳剂
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
RU2008140298A (ru) 2006-03-13 2010-04-20 Р-Тек Уено, Лтд. (Jp) Водная композиция
WO2008035246A2 (en) 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
TWI394564B (zh) 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
ZA200901164B (en) 2006-09-21 2010-06-30 Alcon Res Ltd Self preserved aqueous pharmaceutical compositions
US9364461B2 (en) * 2006-12-21 2016-06-14 Santen Sas Process for manufacturing ophthalmic oil-in-water emulsions
US20080234376A1 (en) * 2007-03-21 2008-09-25 Taiwan Liposome Company (A Taiwan Corporation) Emulsion composition comprising prostaglandin e1
EP1985298A1 (en) * 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins
KR20110010788A (ko) 2008-05-28 2011-02-07 알콘 리서치, 리미티드 자기보존 에멀젼
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP2228057A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Cationic oil-in-water emulsions containing prostaglandins and uses thereof
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions

Also Published As

Publication number Publication date
US9089480B2 (en) 2015-07-28
AU2010220321A1 (en) 2011-09-01
IL214506A0 (en) 2011-09-27
MX2011009256A (es) 2011-09-27
HK1166608A1 (en) 2012-11-02
EP2403478B1 (en) 2016-03-02
US20110319488A1 (en) 2011-12-29
WO2010100217A1 (en) 2010-09-10
CA2754156C (en) 2017-06-06
JP5722802B2 (ja) 2015-05-27
CN102341093B (zh) 2014-08-27
KR101786760B1 (ko) 2017-10-18
CN102341093A (zh) 2012-02-01
CA2754156A1 (en) 2010-09-10
EP2228058A1 (en) 2010-09-15
KR20120003856A (ko) 2012-01-11
AU2010220321B2 (en) 2015-08-20
KR20170052695A (ko) 2017-05-12
JP2012519664A (ja) 2012-08-30
EP2403478A1 (en) 2012-01-11
IL214506A (en) 2016-08-31
KR101879381B1 (ko) 2018-08-16

Similar Documents

Publication Publication Date Title
ES2572373T3 (es) Emulsiones aniónicas aceite en agua que contienen prostaglandinas y usos de las mismas
CU20180097A7 (es) Composición administrable oralmente
ES2531646T3 (es) Composiciones de emulsión farmacéuticas con bajo contenido de aceite que comprenden progestágeno
MX2009011391A (es) Emulsion oftalmica aceite en agua que contiene prostaglandinas.
AR104725A1 (es) Composiciones surfactantes y detergentes que contienen glicerina etoxilada
DE602004024124D1 (de) Floating-auskleidung
JP2010524992A5 (es)
AR051760A1 (es) Nivel reducido de antiempanante en pelicula secuestrante de oxigeno con propiedades antiempanantes
CR11747A (es) Microemulsion mejorada que tiene un amplio rango de aplicacion
AR073457A1 (es) Fluidos de dioxido de cloro no citotoxico, composicion oxidante de irritacion reducida
WO2007042262A3 (en) Ophthalmic emulsions containing prostaglandins
RS20090101A (en) Pickering emulsion formulations
AR093250A1 (es) Composiciones para dar servicio a la perforacion de un pozo y metodos para elaborarlas y usarlas
RS20090096A (sr) Formulacije pickering emulzije
AR092523A1 (es) Proceso para fabricar un agente de estructuracion cristalino
RU2020108079A (ru) Инъекционная фармацевтическая композиция, содержащая мелоксикам, и способ ее получения
AR065032A1 (es) Emulsion dermatologica y procedimiento de preparacion
CO5570649A2 (es) Producto antitranspirante en gel liquido de alta eficiencia
BR112015025554A2 (pt) sistema de nivelamento para suspensão
CL2020002252A1 (es) Formulación oftálmica.
EA201270452A1 (ru) Обратно-эмульсионные текучие среды с высокой концентрацией дисперсной фазы
PE20210413A1 (es) Formulacion liquida estable que comprende etelcalcetida (amg416), un agente tamponante y agente de tonicidad
AR029081A1 (es) Una composicion de enjuague con agentes de beneficio para el cuidado del cabello y la piel en emulsion multiple&#39; agua en aceite en agua &#39;
PE20171432A1 (es) Compuestos de benzoxaborol y uso de los mismos
CL2018003110A1 (es) Preparación y dispersión de formulaciones de emulsión estable.